Femasys is trading 5.13% up in after-hours at $1.64, versus its October 14 regular-session close of $1.56; the reason for the rise is unclear.

  • Shares fell 11.36% during the regular session.
  • On October 14, Femasys announced it had doubled actively enrolling sites in its FemBloc FINALE pivotal trial to twelve; reporting does not establish this as the cause of the after-hours rise.
  • The broader market was sharply lower, leaving a market-wide explanation for the after-hours gain unclear.